2024-01-19 08:30 Regulatory
Biovica, active in cancer monitoring, has signed a collaboration agreement for DiviTum® TKa in Spain and Portugal with the Palex Group, a leading hospital equipment supplier with a proven track record in taking oncology tests and surgical instruments...
2023-12-14 17:20 Regulatory
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND...
2023-12-05 13:00 Regulatory
Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world's largest breast cancer symposium, SABCS, in early December. New clinical research for...
2023-12-01 08:00 Regulatory
Biovica, active in cancer diagnostics, today announces that the company has received a license for Maryland state, the 18th largest state in the US. The license means that Biovica can now perform analysis and report patient samples from all US states...
2023-11-28 17:00 Regulatory
Stockholm, Sweden, November 28, 2023 – On October 23, 2023, Biovica International AB (publ) (“Biovica” or the “Company”) (Nasdaq First North Premier Growth Market: BIOVIC B) announced that the Board of Directors has resolved...
2023-11-28 08:00 Regulatory Interim
Continued sales growth and several commercial agreements signed! Significant events during the second quarter Significant events after the end of the period Webcast:When: 28/11 2023 kl. 15.00 CETWhere: register via lyyti: https://www.lyyti.fi/reg/Biovica_Q2_Earnings_call_2023__Live_Event_2257Broadcast...
2023-11-24 12:30 Regulatory
Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET. Anders Rylander, CEO, Warren Cresswell, President of...
2023-11-23 14:20 Regulatory
The extra general meeting of Biovica International AB (the "Company") was held today on 23 November 2023 and the following resolution was passed by the meeting. Amendments of the articles of association The extra general meeting resolved, in...
2023-11-21 10:00 Regulatory
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments...
2023-11-13 08:00 Regulatory
Today, Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay. “Axlab is a top-5 brand in cancer screening and diagnostics...

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No